Source: Annual Congress 2009 - Animal models of airways inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Aoki, T. Hisada, T. Ishizuka, M. Utsugi, Y. Koga, A. Ono, T. Kawata, N. Sunaga, Y. Iwasaki, N. Yanagitani, K. Dobashi, M. Mori (Maebashi, Japan). Anti-inflammatory and anti-asthmatic effects of resolvin E1 in a mouse model of allergic asthma. Eur Respir J 2009; 34: Suppl. 53, 4736

Member's Comments

No comment yet.

Related content which might interest you: Neutraligands of CXCL12: Anti-inflammatory activity in an allergic model of asthma Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 Neu-164, a novel antioxidant and anti-inflammatory compound reduces lung inflammation in a murine model of allergic asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008 An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Effect of SMP-028, a novel anti-inflammatory agent, on experimental allergic asthma in guinea pig model Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010 Polyphenolic compounds and experimentally induced allergic asthma Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation Year: 2013 Anti-inflammatory effects of sevoflurane anesthesia in an experimental model of chronic allergic asthma Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Ovalbumin-induced asthma model in Brown Norway rats demonstrates potential anti-asthmatic effects of Neu-164, a novel antioxidant and anti-inflammatory compound Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008 Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002 Advantageous toxicity profile of an inhaled GATA-3-specific DNAzyme intended for anti-inflammatory treatment of Th2-driven asthma Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 First line anti-inflammatory treatment for asthma: inhaled steroid or leukotriene antagonist? Source: Eur Respir J 2002; 20: Suppl. 38, 93s Year: 2002 Inhibitory effects of montelukast on mediator release by nasal epithelial cells from asthmatic subjects Source: Annual Congress 2013 –The pulmonary epithelium: recent developments Year: 2013 Effect of oral procaterol on allergic inflammation examined by a murine asthmatic model Source: Eur Respir J 2003; 22: Suppl. 45, 286s Year: 2003 Antitussive and antiinflammatory effect of montelukast in patients with cough variant asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Source: Eur Respir J 2001; 17: 1059-1061 Year: 2001 Antioxidant, γ-glutamylcysteinylethyl ester, ameliorates airway hyperresponsiveness in a mouse asthma model Source: Eur Respir J 2006; 28: Suppl. 50, 224s Year: 2006 Resolvin E1 and E3 dampens asthmatic inflammation in a murine model Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001 Clinical efficacy of leukotriene antagonist in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005 The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014